ProCE Banner Activity

INSIGHT 2: Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib

Conference Coverage
Slideset

Tepotinib plus osimertinib demonstrated activity with a manageable safety profile in patients with MET-amplified, EGFR-mutated advanced NSCLC with disease progression on first-line osimertinib in the phase II INSIGHT 2 trial.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure